Thursday, 1 October 2015

Unrelated Blogger Comments


Posted by at
Labels:

2 comments:

  1. Anonymous23 November 2015 at 22:27

    Any news on the cladribine front? How does it compare to rituximab in terms of relative efficacy?

    ReplyDelete
    Replies
    1. MouseDoctor27 November 2015 at 13:28

      Merck is going back to the EMA to get movectro approaved. In terms of efficacy an rituxumab I believe they will be comparable for RRMS but cladribine can get into the CNS and this will not be the case for rituximab

      Delete

Subscribe to: Post Comments (Atom)